CD109 (Cluster of Differentiation 109) is a cell surface antigen that is linked to glycosyl-phosphatidyl-inositol (GPI). CD109 is also known as platelet-specific Gov antigen, 150 kDa TGF-beta-1-binding protein, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 7, CPAMD7, p180, r150, DKFZp762L1111, FLJ38569, and RP11-525G3.1. It is expressed by CD34+ acute myeloid leukemia cell lines, T-cell lines, activated T lymphoblasts, endothelial cells, and activated platelets. CD109 is considered to be a marker of early-stage megakaryocytic hematopoiesis. Overexpression of CD109 has been reported in squamous cell carcinomas, such as lung carcinoma, esophageal carcinoma, and cervical carcinoma.
These products are affinity-purified IgG antibodies that recognizes human CDC109 protein. The antibodies were raised in mouse or rabbit using a recombinant protein or synthetic peptides, and can be used for Western blot (WB) detection, immunohistochemical (IHC) detection, or immunoprecipitation (IP) of human CD109 protein.